D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Get Pulmonx alerts:Check Out Our Latest Research Report on LUNGPulmonx Stock PerformancePulmonx stock opened at $1.76 on Thursday. Research analysts expect that Pulmonx will post -1.55 earnings per share for the current year. Pulmonx Company Profile(Get Free Report)Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema.